Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 611.26 Billion KRW | -6.79% |
| 2022 | 655.81 Billion KRW | -7.5% |
| 2021 | 708.97 Billion KRW | 17.13% |
| 2020 | 605.27 Billion KRW | -1.22% |
| 2019 | 612.72 Billion KRW | 8.51% |
| 2018 | 564.66 Billion KRW | 0.01% |
| 2017 | 564.62 Billion KRW | 2.59% |
| 2016 | 550.35 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 600.9 Billion KRW | -1.69% |
| 2024 Q2 | 604.71 Billion KRW | 0.63% |
| 2023 Q4 | 611.26 Billion KRW | 4.86% |
| 2023 FY | 611.26 Billion KRW | -6.79% |
| 2023 Q2 | 643.59 Billion KRW | -0.3% |
| 2023 Q1 | 645.55 Billion KRW | -1.56% |
| 2023 Q3 | 582.91 Billion KRW | -9.43% |
| 2022 Q1 | 718.54 Billion KRW | 1.35% |
| 2022 Q4 | 655.81 Billion KRW | -8.32% |
| 2022 Q3 | 715.36 Billion KRW | -2.69% |
| 2022 Q2 | 735.14 Billion KRW | 2.31% |
| 2022 FY | 655.81 Billion KRW | -7.5% |
| 2021 Q2 | 691.56 Billion KRW | 0.83% |
| 2021 Q3 | 697.83 Billion KRW | 0.91% |
| 2021 Q4 | 708.97 Billion KRW | 1.6% |
| 2021 FY | 708.97 Billion KRW | 17.13% |
| 2021 Q1 | 685.86 Billion KRW | 13.31% |
| 2020 Q1 | 613.87 Billion KRW | 0.19% |
| 2020 Q2 | 619.58 Billion KRW | 0.93% |
| 2020 FY | 605.27 Billion KRW | -1.22% |
| 2020 Q4 | 605.27 Billion KRW | -2.89% |
| 2020 Q3 | 623.29 Billion KRW | 0.6% |
| 2019 Q4 | 612.72 Billion KRW | -2.99% |
| 2019 Q3 | 631.57 Billion KRW | -1.09% |
| 2019 Q2 | 638.54 Billion KRW | 1.41% |
| 2019 Q1 | 629.69 Billion KRW | 11.51% |
| 2019 FY | 612.72 Billion KRW | 8.51% |
| 2018 Q2 | 578.78 Billion KRW | -1.23% |
| 2018 Q4 | 564.66 Billion KRW | -0.52% |
| 2018 Q1 | 586 Billion KRW | 3.79% |
| 2018 Q3 | 567.62 Billion KRW | -1.93% |
| 2018 FY | 564.66 Billion KRW | 0.01% |
| 2017 Q3 | 560.55 Billion KRW | 2.07% |
| 2017 Q1 | 546.54 Billion KRW | -0.69% |
| 2017 FY | 564.62 Billion KRW | 2.59% |
| 2017 Q2 | 549.17 Billion KRW | 0.48% |
| 2017 Q4 | 564.62 Billion KRW | 0.73% |
| 2016 FY | 550.35 Billion KRW | 0.0% |
| 2016 Q4 | 550.35 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -208.385% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 68.767% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 30.301% |
| HANDOK Inc. | 790.33 Billion KRW | 22.658% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -258.259% |
| Yuhan Corporation | 2814.07 Billion KRW | 78.278% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 53.524% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -553.902% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 68.686% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -154.961% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -30.36% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -431.655% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -158.408% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -75.455% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -208.385% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -45.82% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -22.307% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -3.71% |
| JW Holdings Corporation | 1176.26 Billion KRW | 48.034% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 56.414% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 5.237% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -74.604% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -296.817% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -64.903% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -25.432% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -208.385% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 43.3% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 65.472% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 5.237% |
| Yuhan Corporation | 2814.07 Billion KRW | 78.278% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 30.538% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -169.752% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 38.489% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 5.237% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -45.573% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -30.372% |
| CKD Bio Corp. | 293.78 Billion KRW | -108.064% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -20.327% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -8.193% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -52.348% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -74.604% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 58.018% |
| Boryung Corporation | 922.36 Billion KRW | 33.729% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -38.15% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -30.36% |
| JW Lifescience Corporation | 255.83 Billion KRW | -138.926% |